Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason G Kettle

Showing results (21-30 of 51) with videos related to

Pageof 6
Sort By:
ACS Chemical Biology|January 5, 2023
Chemical Biology Approaches Confirm MCT4 as the Therapeutic Target of a Cellular Optimized HitAarti Kawatkar, Roger A Clark, Lorna Hopcroft, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 ReceptorsBernard Barlaam, Judith Anderton, Peter Ballard, et al.
Journal of Medicinal Chemistry|March 5, 2015
Discovery and optimization of a novel series of Dyrk1B kinase inhibitors to explore a MEK resistance hypothesisJason G Kettle, Peter Ballard, Catherine Bardelle, et al.
Journal of Medicinal Chemistry|January 18, 2012
Diverse heterocyclic scaffolds as allosteric inhibitors of AKTJason G Kettle, Simon Brown, Claire Crafter, et al.
Bioorganic & Medicinal Chemistry Letters|December 29, 2005
Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocketPeter Ballard, Robert H Bradbury, Craig S Harris, et al.
Journal of the American Chemical Society|May 16, 2020
Alkynyl Benzoxazines and Dihydroquinazolines as Cysteine Targeting Covalent Warheads and Their Application in Identification of Selective Irreversible Kinase InhibitorsKirsten McAulay, Emily A Hoyt, Morgan Thomas, et al.
SLAS Discovery : Advancing Life Sciences R & D|November 29, 2024
High throughput application of the NanoBiT Biochemical Assay for the discovery of selective inhibitors of the interaction of PI3K-p110α with KRASMohamed Ismail, Gareth Davies, Graham Sproat, et al.
Journal of Medicinal Chemistry|December 16, 2022
Discovery of Clinical Candidate AZD0095, a Selective Inhibitor of Monocarboxylate Transporter 4 (MCT4) for OncologyFrederick W Goldberg, Jason G Kettle, Gillian M Lamont, et al.
Bioorganic & Medicinal Chemistry|December 18, 2021
Identification and optimization of a novel series of selective PIP5K inhibitorsDavid M Andrews, Sharon Cartic, Sabina Cosulich, et al.
Journal of Medicinal Chemistry|September 22, 2023
Discovery of the Potent and Selective Inhaled Janus Kinase 1 Inhibitor AZD4604 and Its Preclinical CharacterizationMagnus Nilsson, Kristina Berggren, Susanne Berglund, et al.
Pageof 6

Showing results (21-30 of 51) with videos related to

Sort By:
Pageof 6
ACS Chemical Biology|January 5, 2023
Chemical Biology Approaches Confirm MCT4 as the Therapeutic Target of a Cellular Optimized HitAarti Kawatkar, Roger A Clark, Lorna Hopcroft, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 ReceptorsBernard Barlaam, Judith Anderton, Peter Ballard, et al.
Journal of Medicinal Chemistry|March 5, 2015
Discovery and optimization of a novel series of Dyrk1B kinase inhibitors to explore a MEK resistance hypothesisJason G Kettle, Peter Ballard, Catherine Bardelle, et al.
Journal of Medicinal Chemistry|January 18, 2012
Diverse heterocyclic scaffolds as allosteric inhibitors of AKTJason G Kettle, Simon Brown, Claire Crafter, et al.
Bioorganic & Medicinal Chemistry Letters|December 29, 2005
Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocketPeter Ballard, Robert H Bradbury, Craig S Harris, et al.
Journal of the American Chemical Society|May 16, 2020
Alkynyl Benzoxazines and Dihydroquinazolines as Cysteine Targeting Covalent Warheads and Their Application in Identification of Selective Irreversible Kinase InhibitorsKirsten McAulay, Emily A Hoyt, Morgan Thomas, et al.
SLAS Discovery : Advancing Life Sciences R & D|November 29, 2024
High throughput application of the NanoBiT Biochemical Assay for the discovery of selective inhibitors of the interaction of PI3K-p110α with KRASMohamed Ismail, Gareth Davies, Graham Sproat, et al.
Journal of Medicinal Chemistry|December 16, 2022
Discovery of Clinical Candidate AZD0095, a Selective Inhibitor of Monocarboxylate Transporter 4 (MCT4) for OncologyFrederick W Goldberg, Jason G Kettle, Gillian M Lamont, et al.
Bioorganic & Medicinal Chemistry|December 18, 2021
Identification and optimization of a novel series of selective PIP5K inhibitorsDavid M Andrews, Sharon Cartic, Sabina Cosulich, et al.
Journal of Medicinal Chemistry|September 22, 2023
Discovery of the Potent and Selective Inhaled Janus Kinase 1 Inhibitor AZD4604 and Its Preclinical CharacterizationMagnus Nilsson, Kristina Berggren, Susanne Berglund, et al.
Pageof 6